在阿尔茨海默病进展期间线粒体数量密度的特定区域的起伏:人类大脑的试点研究
Anna-Lena Balsliemke1, Barbara Ahlemeyer1, Eugen Schmidl1
1Institute for Anatomy and Cell Biology, Division of Medical Cell Biology, Justus-Liebig University, Gießen, Germany.
Journal of Alzheimer's disease : JAD
|March 6, 2026
概括
阿尔茨海默病 (AD) 改变了人类大脑中的线粒体密度. 神经元线粒体在新皮质增加,但在海马体减少,与神经病理变化相关.
科学领域:
- 神经科学是一个神经科学.
- 神经病理学神经病理学
- 线粒体生物学 线粒体生物学
背景情况:
- 线粒体功能障碍是阿尔茨海默病 (AD) 进展的关键因素.
- 以前的研究重点是线粒体代谢,氧化应激和动态.
- 关于人类AD大脑中线粒体数值密度变化的数据有限.
研究的目的:
- 在阿尔茨海默氏症神经病理变化 (ADNC) 的不同阶段,研究人类大脑各个区域线粒体数量密度的变化.
- 为了比较AD中的线粒体密度变化与陶氏病和对照大脑中的变化.
主要方法:
- 使用ATP5B标记物的形态测量分析来自阿尔茨海默病,病症和对照患者的13个区域的大脑部分.
- 根据ADNC水平的ABC分数对患者样本的分类.
- 在神经元群体中对线粒体数值密度的定量分析.
主要成果:
- 在AD患者的前额和皮新皮质,核和大脑小脑Purkinje神经元中观察到线粒体密度的增加.
- 在海马神经元 (脑内皮层,CA3) 中和高ADNC中发现的线粒体密度下降.
- 病患者的相似变化,内皮层的减少和内皮层的增加更明显.
结论:
- 神经元线粒体密度在新皮质中增加,与粉样β (Aβ) 沉积有关.
- 神经元线粒体密度在海马体下降,与神经纤维状结有关.
- 在阿尔茨海默病和陶病症大脑中,线粒体密度的改变显示出特定区域的模式.
相关概念视频
Alzheimer's Disease: Overview
1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Mitochondria
21.1K
Mitochondria are eukaryotic cellular organelles that are known to produce energy through a process called oxidative phosphorylation. Besides their primary function, mitochondria are involved in various cellular processes, including cell growth, differentiation, signaling, metabolism, and senescence. Age-related changes cause a decline in mitochondrial quality and integrity due to increased mitochondrial mutations and oxidative damage. Thus, aging can severely impact mitochondrial functions,...
21.1K
Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K


